Patents by Inventor Daifu Zhou

Daifu Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRUG FOR INHIBITING ADIPOSE CELL DIFFERENTIATION AND INSULIN RESISTANCE
    Publication number: 20220409703
    Abstract: The present invention provides use of endostatin or a functional variant thereof in the preparation of a medicament for treating dietary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In the embodiments of the present invention, the functional variant may be YH-16, mES, mYH-16, m003, m007, mZ101, or the like.
    Type: Application
    Filed: July 20, 2022
    Publication date: December 29, 2022
    Inventors: Yongzhang LUO, Hui WANG, Hui LI, Xinan LU, Yan FU, Shunli ZHAN, Daifu ZHOU
  • Pegylated endostatin analogue and application thereof
    Patent number: 11098104
    Abstract: The present invention provides a polyethylene glycol-modified endostatin analogue and an application thereof. The endostatin analogue is coupled to polyethylene glycol at lysine away from a nucleolin binding domain, or is coupled to polyethylene glycol at lysine away from a nucleolin binding domain and amidogen at the N end.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 24, 2021
    Assignee: BEIJING PROTGEN LTD.
    Inventors: Daifu Zhou, Wenchao Wang, Hui Li, Guodong Chang
  • PEGYLATED ENDOSTATIN ANALOGUE AND APPLICATION THEREOF
    Publication number: 20200270333
    Abstract: The present invention provides a polyethylene glycol-modified endostatin analogue and an application thereof. The endostatin analogue is coupled to polyethylene glycol at lysine away from a nucleolin binding domain, or is coupled to polyethylene glycol at lysine away from a nucleolin binding domain and amidogen at the N end.
    Type: Application
    Filed: November 10, 2017
    Publication date: August 27, 2020
    Applicant: BEIJING PROTGEN LTD.
    Inventors: Daifu Zhou, Wenchao Wang, Hui Li, Guodong Chang
  • Endostatin mutants with mutations at ATP binding sites
    Patent number: 10647968
    Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: May 12, 2020
    Assignees: Tsinghua University, Beijing Protgen Ltd.
    Inventors: Yongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou
  • DRUG FOR INHIBITING ADIPOSE CELL DIFFERENTIATION AND INSULIN RESISTANCE
    Publication number: 20180015148
    Abstract: The present invention provides use of endostatin or a functional variant thereof in the preparation of a medicament for treating dietary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In the embodiments of the present invention, the functional variant may be YH-16, mES, mYH-16, m003, m007, mZ101, or the like.
    Type: Application
    Filed: November 3, 2015
    Publication date: January 18, 2018
    Applicants: TSINGHUA UNIVERSITY, BEIJING PROTGEN LTD.
    Inventors: Yongzhang LUO, Hui WANG, Hui LI, Xinan LU, Yan FU, Shunli ZHAN, Daifu ZHOU
  • ENDOSTATIN MUTANTS WITH MUTATIONS AT ATP BINDING SITES
    Publication number: 20150197733
    Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.
    Type: Application
    Filed: September 10, 2012
    Publication date: July 16, 2015
    Applicants: BEIJING PROTGEN LTD., TSINGHUA UNIVERSITY
    Inventors: Yongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou
  • ENDOSTATIN MUTANTS WITH MUTATIONS AT ATP BINDING SITES
    Publication number: 20140308263
    Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.
    Type: Application
    Filed: September 10, 2012
    Publication date: October 16, 2014
    Applicants: BEIJING PROTGEN LTD., TSINGHUA UNIVERSITY
    Inventors: Yongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou